Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurogene (NGNE) Change in Accured Expenses (2018 - 2025)

Historic Change in Accured Expenses for Neurogene (NGNE) over the last 6 years, with Q3 2025 value amounting to $365000.0.

  • Neurogene's Change in Accured Expenses fell 8618.47% to $365000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$409000.0, marking a year-over-year increase of 9281.45%. This contributed to the annual value of -$2.8 million for FY2024, which is 2241.19% up from last year.
  • Per Neurogene's latest filing, its Change in Accured Expenses stood at $365000.0 for Q3 2025, which was down 8618.47% from $2.2 million recorded in Q2 2025.
  • In the past 5 years, Neurogene's Change in Accured Expenses ranged from a high of $2.6 million in Q3 2024 and a low of -$4.9 million during Q1 2024
  • Its 3-year average for Change in Accured Expenses is -$546636.4, with a median of $207000.0 in 2024.
  • As far as peak fluctuations go, Neurogene's Change in Accured Expenses plummeted by 9963.18% in 2024, and later surged by 94927.54% in 2025.
  • Neurogene's Change in Accured Expenses (Quarter) stood at -$3.7 million in 2023, then soared by 79.71% to -$743000.0 in 2024, then soared by 149.13% to $365000.0 in 2025.
  • Its Change in Accured Expenses stands at $365000.0 for Q3 2025, versus $2.2 million for Q2 2025 and -$2.2 million for Q1 2025.